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Intensive care medicine: a specialty coming to LIFE
The Lancet today includes three papers about intensive 
care medicine. The papers describe the evolution of 
the specialty,1 the demand for and ability to supply 
appropriate levels of care,2 and some of the commonly 
faced ethical dilemmas and challenges.3 These topics 
are apt in this period of economic constraint. Intensive 
care medicine consumes a considerable proportion of 
health-care resources4 and these costs will need to be 
justiﬁ ed. The appropriateness and eﬀ ectiveness of the 
care provided will need to be improved to ensure that 
these resources are directed to patients most in need of 
them. Intensive care medicine is the science and art of 
preventing, caring for, and when possible curing acutely 
unwell patients. It is a young specialty, originating from 
the 1952 Copenhagen poliomyelitis epidemic5,6 and the 
subsequent realisation that multisystem monitoring, 
support, and reanimation are often required.7,8
Jean-Louis Vincent and Mervyn Singer1 review the 
improvements in practice that have been made over 
the past few decades and extrapolate forward. What 
is striking is the fact that despite the expenditure of 
a great amount of time, energy, and resources, the 
search for a cure-all magic bullet has failed. What has 
become apparent, however, is the need for a greater 
understanding of the basic processes involved in the care 
of sick patients, and how this increased understanding 
can be used to improve patient outcomes. Intensive 
care medicine has evolved from being mainly driven 
by new technologies, often on the basis of the practical 
application of well-known physiological principles, to 
a more holistic, proactive, patient-centred approach. 
In the past, there was a perception that intensive care 
medicine was about only looking at and mostly reacting 
to numbers. This approach was unsurprising when past 
intensive-care units are considered—the machines often 
outnumbered the patients and hid them behind cloaks 
of mystique. When new concepts and technologies are 
introduced into practice, it is all too easy to focus on 
only the potential beneﬁ ts. With some techniques, these 
beneﬁ ts are obvious; sadly however, with many, these 
beneﬁ ts must be weighed against the potential for 
harm. The balance can be ﬁ ne and might only become 
apparent after many years.9 We should be open-minded 
enough to adopt new theories and practices, but not 
without suitable cynicism so as to not add further risk. 
Intensive care medicine is about the combination of 
high-intensity hands-on care with the rational use of 
modern technology. Understanding the limitations of 
what can be done—often for elderly frail patients with 
multiple comorbidities—is crucially important and needs 
appropriate numbers of accredited specialists.
Neill Adhikari and colleagues2 describe the increased 
global burden of critical illness and the implications of 
this increase on staﬃ  ng structures. The need to attract 
young trainee doctors to intensive care medicine is 
obvious. In the USA, attempts to meet the challenge 
are based on the creation of a new class of physician 
extenders, nursing practitioners, and telemedicine. Most 
European countries have taken a diﬀ erent stance by 
aiming to increase the number of new specialists capable 
of delivering this care. For this reason, the European 
Board of Intensive Care Medicine believes that we need 
to increase the recognition of intensive care medicine 
within European legislation. Intensive care medicine 
is not yet described as a specialty,10 which has obvious 
implications for its proﬁ le, ability to attract trainees, 
and the overall quality of care. Quality of care should 
be eﬀ ective, safe, and accessible. We should therefore 
continue to improve our understanding of how the 
structures and processes that underpin care pathways 
inﬂ uence overall outcomes. For this reason, the 
European Society of Intensive Care Medicine (ESICM), 
together with more than 60 other national societies 
in intensive care medicine, signed the Declaration of 
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Kidneys donated after cardiac death are acceptable
Dominic Summers and colleagues, in The Lancet today,1 
have carefully analysed the factors that aﬀ ect outcome 
after transplantation of kidneys from deceased donors 
in the UK. Outcomes were for kidneys donated after 
cardiac death (cessation of cardiac activity) and after 
brain-stem death. Today’s analysis includes more than 
9000 recipients of kidney transplants from 2000 to 
2007, during which time 10% of patients received a 
kidney from a cardiac-death donor and the remaining 
patients received kidneys from brain-death donors.
Over the past 2–3 years, the use of cardiac-death donors 
has increased substantially in the UK and almost 30% of 
all deceased donor kidneys used in renal transplantation 
are from cardiac-death donors.2 The rising demand for 
kidneys for transplantation and the decreasing number 
of brain-death donors has led to the increasing use 
of cardiac-death donors. Kidneys from cardiac-death 
donors are regarded as marginal kidneys; there has 
therefore been concern that their use would lead to 
an increase in delayed graft function, which would be 
reﬂ ected by impaired renal function and poorer graft 
survival. Summers and colleagues conﬁ ned their analysis 
to Maastricht category 3 donors, namely controlled 
cardiac-death donors,3 which means removal of kidneys 
after cessation of cardiac activity in the donor following 
withdrawal of respiratory and circulatory support. It 
should be remembered that in the 1970s, before brain-
stem death was accepted as a diagnosis of death, all 
kidneys were retrieved after cessation of cardiac activity, 
mostly in a controlled situation, and were the equivalent 
of Maastricht 3 donors. Excellent results were obtained 
with the immunosuppression available at that time, 
even though delayed graft function occurred in 10–50% 
of recipients.4,5
In today’s analysis, delayed graft function was 
increased in kidneys from cardiac-death donors (50%) 
compared with kidneys from brain-death donors (25%). 
Estimated glomerular ﬁ ltration rate (after adjustment 
for possible confounding factors) was inferior at 
3 months in recipients of kidneys from cardiac-death 
Vienna,11 openly pledging to direct resources and time 
towards improving the quality and safety of care for 
sick patients. However, quality should also be assessed 
both from the perspectives of health-care professionals 
and from the patient or their surrogate. This experience 
of care is the ﬁ fth domain of quality from the National 
Quality Measures Clearinghouse.12 In October, 2010, 
ESICM is therefore launching their Linking Intensive Care 
to Family Experience (LIFE) campaign in Barcelona. This 
campaign is an attempt to continue to improve quality, 
but by including the views of patients and their partners. 
Only with this domain can we be sure that what we 
believe is quality is what will really make the diﬀ erence. 
As Henry Ford described, “quality is doing it right when 
no one is looking”.
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